Table 2.
Ref. | Design | Cases | Technical success | Clinical success | Recurrence | Complications1 |
Binmoeller et al[8] | RS | 27 | 93% | 78% | 22% | 52% |
Pfaffenbach et al[9] | PS | 11 | 91% | 82% | 18% | None |
Giovannini et al[10] | PS | 35 | 100% | 89% | 9% | 3% |
Norton et al[11] | RS | 14 | 93% | 93% | 23% | 14% |
Vosoghi et al[12] | RS | 14 | 100% | 93% | 7% | 7% |
Enya et al[13] | PS | 13 | 100% | 85% | 0% | None |
Hookey et al[14] | RS | 32 | 96% | 93% | 12% | 11% |
Krüger et al[15] | PS | 35 | 94% | 88% | 12% | 33% |
Azar et al[16] | RS | 23 | 91% | 82% | 18% | 4% |
Antillon et al[17] | PS | 33 | 94% | 87% | 4% | 15% |
Kahaleh et al[18] | PS | 46 | 100% | 93% | NR | 19% |
Ahlawat et al[19] | PS | 11 | 100% | 82% | 18% | 18% |
Arvanitakis et al[20] | RCT | 46 | 100% | 94% | 11% | 22% |
Lopes et al[21] | RS | 51 | 94% | 84% | 17% | 25% |
Varadarajulu et al[22] | PS | 23 | 100% | 95% | 0% | None |
Lopes et al[23] | PS | 31 | 100% | 94% | 19% | 26% |
Ardengh et al[24] | PS | 77 | 94% | 91% | 11% | 6% |
Varadarajulu et al[25] | RS | 20 | 100% | 95% | NR | None |
Varadarajulu et al[26] | RCT | 24 | 100% | 96% | NR | 4% |
Varadarajulu et al[27] | PS | 60 | 95% | 93% | 4% | 2% |
Barthet et al[28] | PS | 28 | 100% | 89% | NR | 25% |
Talreja et al[29] | PS | 18 | 100% | 95% | 0% | 44% |
Park et al[30] | RCT | 39 | 95% | 95% | 6% | 7% |
Yasuda et al[31] | RS | 26 | 92% | 87% | 17% | None |
Itoi et al[32] | PS | 13 | 100% | 100% | 0% | None |
Varadarajulu et al[33] | PS | 10 | 100% | 90% | 0% | None |
Ang et al[34] | PS | 10 | 100% | 100% | 0% | 10% |
Ahn et al[35] | RS | 47 | 98% | 100% | 11% | 11% |
Jazrawi et al[36] | RS | 10 | 100% | 100% | 10% | None |
Sadik et al[37] | PS | 26 | 100% | 88% | 4% | 15% |
Will et al[38] | PS | 132 | 97% | 96% | 15% | 29% |
Seicean et al[39] | PS | 24 | 83% | 79% | 0% | 17% |
Heinzow et al[40] | RS | 42 | 88% | 78% | 21% | 21% |
Varadarajulu et al[41] | PS | 148 | 100% | 99% | NR | 5% |
Varadarajulu et al[42] | RS | 602 | 100% | 69% | 0% | 8% |
Varadarajulu et al[43] | RS | 20 | 100% | 100% | 5% | None |
Zheng et al[44] | PS | 14 | 90% | 90% | 0% | 19% |
Voermans et al[45] | RCT | 52 | 100% | 82% | 9% | 11% |
Mangiavillano et al[46] | PS | 21 | 86% | 81% | 14% | 5% |
Seewald et al[47] | RS | 80 | 97% | 83% | 13% | 26% |
Itoi et al[48] | RS | 15 | 100% | 100% | 0% | 6% |
Puri et al[49] | PS | 40 | 100% | 97% | 2% | 7% |
Fabbri et al[50] | PS | 20 | 100% | 95% | 5% | 15% |
Rasmussen et al[51] | RS | 22 | 86% | 86% | 18% | 18% |
Khashab et al[52] | RS | 10 | 100% | 100% | 0% | None |
Penn et al[53] | PS | 20 | 100% | 85% | 18% | 15% |
Weilert et al[54] | PS | 18 | 100% | 78% | NR | 33% |
Rana et al[55] | RS | 202 | 100% | 100% | 0% | 5% |
Binmoeller et al[56] | RS | 14 | 100% | 79% | NR | 21% |
Nan et al[57] | RS | 21 | 100% | 100% | NR | 5% |
Kato et al[58] | RS | 67 | 88% | 83% | 15% | 1% |
Künzli et al[59] | RS | 108 | 97% | 84% | 18% | 20% |
Siddiqui et al[60] | RS | 88 | 99% | 79% | 3% | 30% |
Rische et al[61] | RS | 18 | 100% | 94% | 6% | 33% |
Varadarajulu et al[62] | RCT | 20 | 100% | 95% | 0% | None |
Total | 55 studies | 1867 | 97% (83%-100%) | 90% (69%-100%) | 8% (0%-23%) | 17% (0%-52%) |
Complications include: early and late, procedural and stent related;
Only patients with walled-off pancreatic necrosis. RCT: Randomized controlled trial; PS: Prospective study; RS: Retrospective study; NR: Not reported.